BBC icon

Virtus LifeSci Biotech Clinical Trials ETF
BBC

Overview Fund Trends Analyst Outlook Journalist POV

18 hedge funds and large institutions have $7.19M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 6

Holders
18
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$8K
2
+$6K
3
+$3K

Top Sellers

1
-$379K
2
-$264K
3
-$226K
4
FTUS
Flow Traders U.S.
New York
-$210K
5
Morgan Stanley
Morgan Stanley
New York
-$22.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$2.79M
2
$2.38M
3
$1.06M
4
$530K
5
$188K
6
$72K
7
$47K
8
$28K
9
$23.4K
10
$18K
11
$17K
12
$8K
13
$6K
14
$6K
15
$3K
16
$3K
17
$1K
18
–
19
–
20
–